Paclitaxel 6 mg/ml concentrate for solution for infusion Ireland - English - HPRA (Health Products Regulatory Authority)

paclitaxel 6 mg/ml concentrate for solution for infusion

fresenius kabi deutschland gmbh - paclitaxel - concentrate for solution for infusion - 6 milligram(s)/millilitre - taxanes; paclitaxel

PACLITAXEL ALPHAPHARM paclitaxel 30 mg/5 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel alphapharm paclitaxel 30 mg/5 ml concentrated injection vial

alphapharm pty ltd - paclitaxel -

PACLITAXEL ALPHAPHARM paclitaxel 100 mg/16.7 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel alphapharm paclitaxel 100 mg/16.7 ml concentrated injection vial

alphapharm pty ltd - paclitaxel -

PACLITAXEL ALPHAPHARM paclitaxel 300 mg/50 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel alphapharm paclitaxel 300 mg/50 ml concentrated injection vial

alphapharm pty ltd - paclitaxel -

PACLITAXEL INTAS paclitaxel 300 mg/50 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel intas paclitaxel 300 mg/50 ml concentrated injection vial

accord healthcare pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; ethanol absolute - - primary treatment of ovarian cancer in combination with a platinum agent. - treatment of metastatic carcinoma of the ovary after failure of standard therapy. - treatment of metastatic carcinoma of the breast after failure of standard therapy. - adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. - treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. - in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. - for the treatment of non-small cell lung cancer (nsclc).

PACLITAXEL INTAS paclitaxel 100 mg/16.7 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel intas paclitaxel 100 mg/16.7 ml concentrated injection vial

accord healthcare pty ltd - paclitaxel, quantity: 100 mg - injection, concentrated - excipient ingredients: ethanol absolute; peg-35 castor oil - - primary treatment of ovarian cancer in combination with a platinum agent. - treatment of metastatic carcinoma of the ovary after failure of standard therapy. - treatment of metastatic carcinoma of the breast after failure of standard therapy. - adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. - treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. - in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. - for the treatment of non-small cell lung cancer (nsclc).

PACLITAXEL INTAS paclitaxel 30 mg/5 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel intas paclitaxel 30 mg/5 ml concentrated injection vial

accord healthcare pty ltd - paclitaxel, quantity: 30 mg - injection, concentrated - excipient ingredients: ethanol absolute; peg-35 castor oil - - primary treatment of ovarian cancer in combination with a platinum agent.. - treatment of metastatic carcinoma of the ovary after failure of standard therapy. - treatment of metastatic carcinoma of the breast after failure of standard therapy. - adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. - treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease. - in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. - for the treatment of non-small cell lung cancer (nsclc).

PACLITAXEL ACC paclitaxel 300 mg/50 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel acc paclitaxel 300 mg/50 ml concentrated injection vial

accord healthcare pty ltd - paclitaxel, quantity: 300 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; ethanol absolute - - primary treatment of ovarian cancer in combination with a platinum agent.. - treatment of metastatic carcinoma of the ovary after failure of standard therapy.. - treatment of metastatic carcinoma of the breast after failure of standard therapy.. - adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.. - treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin?), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease.. - in combination with gemcitabine (gemzar?), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - for the treatment of non-small cell lung cancer (nsclc).

PACLITAXEL SZ paclitaxel 300mg/50mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel sz paclitaxel 300mg/50ml solution for injection vial

alphapharm pty ltd - paclitaxel -

PACLITAXEL SZ paclitaxel 100mg/16.7mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel sz paclitaxel 100mg/16.7ml solution for injection vial

alphapharm pty ltd - paclitaxel -